10
Participants
Start Date
February 14, 2022
Primary Completion Date
December 6, 2023
Study Completion Date
December 6, 2023
BMS-986218
Specified dose on specified days
Docetaxel
Specified dose on specified days
Nivolumab
Specified dose on specified days
Local Institution - 0021, Rozzano
Local Institution - 0037, Milan
The Johns Hopkins Hospital, Baltimore
Duke Cancer Institute, Durham
Local Institution - 0004, Marietta
Local Institution - 0003, Toulouse
Local Institution - 0016, Modena
Local Institution - 0071, Meldola
University Of Iowa Hospitals And Clinics, Iowa City
Medical College of Wisconsin, Milwaukee
Texas Oncology, Flower Mound
Texas Oncology-Beaumont Mamie McFaddin Ward Cancer Center, Beaumont
Local Institution - 0029, Pozzuoli
Willamette Valley Cancer Institute, Eugene
Arizona Oncology - Tucson - Wilmot Road Location, Tucson
Kaiser Permanente Los Angeles Medical Center, Los Angeles
Rocky Mountain Cancer Centers - Littleton, Littleton
Yale School Of Medicine, New Haven
Medical Oncology Hematology Consultants - Newark, Newark
The Winship Cancer Institute of Emory University, Atlanta
The University of Chicago Medical Center - Duchossois Center for Advanced Medicine, Chicago
Washington University School of Medicine in St. Louis, St Louis
Local Institution - 0006, New York
Oncology Hematology Care, Inc. - Eastgate, Cincinnati
Texas Oncology, Bedford
Texas Oncology - Denton North, Denton
Texas Oncology - Fort Worth Cancer Center, Fort Worth
The University of Texas - MD Anderson Cancer Center - Genitourinary (GU) Cancer Center, Houston
Texas Oncology - McKinney, McKinney
Texas Oncology- Tyler, Tyler
Local Institution - 0056, Hampton
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY